ResaPura

ResaPura Lavorazione Canapa per conto terzi. Cosmetici cbd/cbg

27/05/2026

Basal Cell Carcinoma is the most common cancer in the world.

Most people are told the only real options are surgery, cutting, burning, or radiation. But this published case report tells a very different story.

A patient with basal cell carcinoma applied THC FECO topically to the lesion 4x daily. No chemo. No radiation. No surgery. Just FECO.

In 2 weeks, the carcinoma was completely gone.
10 months later? Still gone.

This wasn’t a random internet post. It was discussed in a formal medical journal article:
“Cannabidiol and Other Phytocannabinoids as Cancer Therapeutics.”

We’re constantly told cannabis has “no evidence.” Meanwhile, outcomes like this keep showing up in the literature — and most people never hear about them.

The question isn’t whether we should replace medicine with cannabis.
The question is: why are documented outcomes like this ignored?

Source:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9021107

25/05/2026

Cannabinoids may do more than sit on top of the skin. Research suggests they can interact with deeper skin signals tied to immune response, inflammation, itch, pain, and oil production.
Acne, eczema, psoriasis, and chronic irritation often involve the skin barrier, immune cells, and inflammatory signals working out of balance.
The ECS, our Master Regulator, is active in the skin too. Cannabinoids can also talk to receptors in the gut through the skin this way. The gut has CB1 and CB2 receptors, plus other targets like TRP channels, that help control movement, inflammation, pain signals, appetite, and immune response.

10/05/2026

📢 New Study: Cannabigerol (CBG) and rheumatoid arthritis 🔬
🔹 Ex vivo human neutrophils + collagen antibody-induced arthritis mouse model
🔹 Human blood neutrophils; C57BL/6 wild-type mice
🔹 CBG reduced cytokines, inflammatory signaling, migration, joint leukocyte recruitment, and improved mouse arthritis scores/body weight
⚠️ Preclinical findings; further validation needed before therapeutic positioning
🔗 https://f.mtr.cool/xsoasyvgwk

06/05/2026

CBGa (Cannabigerolic Acid) and Its Role in Pancreas Health and Diabetes: "CBGa is the precursor molecule to other cannabinoids, such as THC, CBD, and CBC. Emerging research suggests that CBGa and its derivatives may have potential therapeutic benefits for various conditions, including diabetes.

Pancreas Health: CBGa has been found to have anti-inflammatory and antioxidant properties, which are crucial for protecting pancreatic cells from damage. Inflammation and oxidative stress are key factors in the progression of diabetes, especially in destroying insulin-producing beta cells in the pancreas. By reducing inflammation, CBGa may help preserve the function of these cells, improving insulin production and regulation.

Diabetes Management: Although direct research on CBGa and diabetes is still in its early stages, related cannabinoids like CBD and CBG (Cannabigerol, derived from CBGa) have shown promise in improving insulin sensitivity and reducing blood glucose levels in diabetic models. CBGa's role as a precursor suggests that it might also contribute to these effects, especially when combined with other cannabinoids.

Importance of AEA (Anandamide) and 2-AG in Modulating Insulin Levels:

Anandamide (AEA) and 2-Arachidonoylglycerol (2-AG) are the two primary endocannabinoids in the human body, and both play crucial roles in the regulation of insulin levels and overall metabolic health.

AEA interacts mainly with the CB1 receptors, which are found abundantly in the brain and peripheral tissues, including the pancreas. Elevated AEA levels have been associated with increased insulin resistance, particularly in obese individuals. This suggests that maintaining balanced AEA levels is crucial for preventing and managing diabetes. In diabetic patients, controlling AEA levels could improve insulin sensitivity and glucose metabolism.

2-AG also interacts with both CB1 and CB2 receptors and modulates energy balance and insulin secretion. Research has shown that 2-AG levels are often dysregulated in individuals with obesity and type 2 diabetes, leading to impaired insulin signaling. Restoring the balance of 2-AG may help improve insulin sensitivity and glucose homeostasis.

Maintaining a balanced ECS is not achieved through a single action or product; it requires a holistic and ongoing commitment to overall health. Key factors include:

Consuming a diet rich in omega-3 fatty acids, antioxidants, and other nutrients supports the production and function of endocannabinoids. Avoiding processed foods and excessive sugar intake is also crucial, as these can disrupt ECS balance and contribute to metabolic disorders.

Regular physical activity is known to boost endocannabinoid levels, particularly AEA, which can enhance mood, reduce stress, and improve metabolic health. Exercise also plays a role in maintaining insulin sensitivity and overall energy balance.

Using a combination of cannabinoids, such as CBGa, CBD, and minor cannabinoids, in conjunction with THC, can help modulate the ECS. These cannabinoids work synergistically, known as the entourage effect, to provide a more balanced and effective therapeutic outcome. For instance, CBD can counteract some of the psychoactive effects of THC, making it more tolerable for individuals while also providing anti-inflammatory and anti-diabetic benefits.

The inclusion of CBGa, alongside other cannabinoids, offers a comprehensive approach to managing diabetes. The combined effects of these cannabinoids can reduce inflammation and oxidative stress in pancreatic cells and improve insulin sensitivity and glucose metabolism as well as provide neuroprotective effects, which are crucial for preventing complications related to diabetes.

Maintaining a balanced ECS is integral to managing metabolic health, including insulin regulation and diabetes prevention. This balance is achieved through a commitment to a healthy lifestyle - proper nutrition, regular exercise, and the strategic use of cannabinoids like CBGa, CBD, and THC.

Much more research is needed, but what we know is very promising by past research on endocannabinoids themselves. By putting the puzzle pieces together and addressing the ECS holistically, we can harness its potential to prevent and manage diabetes effectively."

-Mike Robinson, The Researcher OG, Founder Global Cannabinoid Research Center

17/04/2026

🔬 New Study Spotlight in Cannabinoid Medicine

What happens when rigorous science meets real-world patient outcomes?

A new publication in Med Cannabis Cannabinoids explores the quantitative impact of cannabinoid therapy in prostate cancer, integrating biomarkers, imaging, and clinical outcomes—an important step toward evidence-based precision care.

Even more exciting, this work features collaboration from Dr. Shiksha Gallow, Board Member at the Society of Cannabis Clinicians—highlighting the growing leadership and global contribution of SCC experts in advancing cannabinoid science.

🌍 This is what progress looks like:
• Multidisciplinary research
• Data-driven insights
• Clinician-led innovation

As the field evolves, studies like this help bridge the gap between clinical experience and measurable outcomes—a critical move for wider medical acceptance and better patient care.

📖 A must-read for clinicians, researchers, and anyone shaping the future of cannabinoid therapeutics.

🌿Link in bio

12/04/2026

Arthritis pain is not just wear and tear; it’s an inflammatory storm inside the joint that keeps feeding stiffness, swelling, and damage. In “Cannabinoids in the Inflamed Synovium Can Be a Target for the Treatment of Osteoarthritis and Rheumatoid Arthritis” (2024), researchers reviewed how endocannabinoids, phytocannabinoids, and synthetic cannabinoids act in inflamed synovial tissue and outlined their potential to reduce both pain and inflammation in osteoarthritis and rheumatoid arthritis.

The review focuses on cannabinoid signaling within the joint itself, where synovial inflammation drives both pain and structural decline.

That’s what makes this paper useful. It does not treat cannabinoids like simple pain blockers. It places them inside the biology of arthritis, where they may influence inflammatory mediators, immune cell behavior, and the tissue environment that keeps joints irritated.

The authors specifically frame cannabinoids as potential tools to reduce the inflammation and pain processes typical of OA and RA, which is a much stronger conversation than just saying cannabis helps aches.

That matters because arthritis relief is not only about dulling a pain signal after it starts. Real control means shifting the joint away from an inflammatory state that keeps reloading the pain pathway. This review does not prove every cannabinoid works for every patient or every form of arthritis, but it does support the idea that cannabinoids may help both sides of the problem at once - pain control and inflammatory balance.

That’s exactly why this science deserves serious attention in arthritis, especially when standard approaches often focus more on symptom suppression than restoring joint-level balance.

-Mike Robinson, The Researcher OG
Study Link: https://www.mdpi.com/1422-0067/25/17/9356

09/04/2026

Autoimmune disease is the body staying stuck in a bad inflammatory conversation, where immune signals keep firing when they should be standing down. In “Cannabinoids and autoimmune diseases: A systematic review” (2016), Katchan and colleagues reviewed how cannabinoids influence immune signaling across autoimmune conditions and found that these compounds can modulate neurotransmitter and cytokine release, suppress leukocyte proliferation, induce apoptosis in T cells and macrophages, and reduce pro inflammatory cytokine output.

The review also notes preclinical benefits in models of arthritis, multiple sclerosis, and type 1 diabetes, while acknowledging that human evidence remains limited and inconclusive.

That’s what makes cannabinoids important in autoimmune inflammation. They are not just being discussed as pain relievers. They are being studied as immune modulators that may help calm part of the inflammatory machinery itself.

This review specifically describes cannabinoids as having immunosuppressive and anti-fibrotic promise in autoimmune disorders, which matters because autoimmune damage is often driven by cells remaining activated too long, releasing excess inflammatory signals, and perpetuating tissue injury over time.

The honest part is just as important - this is not proof that every cannabinoid helps every autoimmune disease, and it is not a license to overstate the science. The review makes clear that most of the stronger evidence was preclinical, while human trials were still scarce.

But the reason this lane keeps growing is simple. Cannabinoids appear capable of dialing down parts of the immune overreaction that drive autoimmune inflammation, and that puts them in a serious conversation about restoring balance where the body has lost it.

-Mike Robinson, The Researcher OG
Study Link: https://doi.org/10.1016/j.autrev.2016.02.008

09/04/2026

Bone pain is one of the hardest pains to shut down because it is not just pain signaling; it is inflammation, nerve irritation, tumor or injury-driven remodeling, and structural breakdown all feeding each other at once. In “A cannabinoid 2 receptor agonist attenuates bone cancer-induced pain and bone loss” (2010), Lozano-Ondoua and colleagues showed that activating CB2 reduced spontaneous and evoked bone pain in a murine model, while also reducing bone loss.

That matters because this was not just a blunt force numbing effect. It pointed to cannabinoid biology working deeper in the disease process that helps generate the pain in the first place.

What separates this from many standard approaches is that many conventional pain care approaches mainly try to quiet the perception of pain after the signal is already firing. In this study, the CB2 agonist AM1241 did more than reduce pain behavior.

Sustained treatment also reduced bone loss and lowered the incidence of cancer-induced bone fractures, suggesting an effect on the destructive environment driving the pain, not only on the sensation itself. That is a serious distinction in bone pain, where the source is often ongoing tissue destruction and inflammatory signaling that keeps reloading the pathway.

That does not mean every cannabinoid product will act like a targeted CB2 agonist, and this study was in a bone cancer model, not every form of orthopedic or degenerative bone pain. But it gives a strong mechanistic reason why cannabinoids stay in the bone pain conversation.

Some cannabinoid pathways may help dull pain by interrupting the biology feeding the signal, while other methods often chase the signal after it is already screaming. That is a very different kind of pain control, and it is one worth paying attention to.

-Mike Robinson, The Researcher OG
Study Link: https://doi.org/10.1016/j.lfs.2010.02.014

11/02/2026

Sometimes “there’s nothing we can do” is just code for we’re not allowed to try.

Drayk didn’t get a hopeful prognosis. He got dismissed.

Nasal cancer. Visible lesion. Antibiotics that did nothing. The vet was clear: no conventional options.

So Drayk’s owners went rogue.

They used THC FECO mixed with coconut oil—applied directly in the nose, with small amounts swallowed—alongside serrapeptase, yunnan baiyao, and turmeric (with black pepper + ginger).

The response was fast.
The vet wasn’t optimistic… until two weeks later when he was shocked by the progress and told them not to stop.

By one month, the cancer was gone. Completely.

Drayk was groggy at first from the THC. That passed. The results didn’t.

The cancer never came back. He lived another 10 months cancer-free until he unfortunately passed from an unrelated issue (bloat).

This is a patient-reported outcome. Not a promise. Not a pitch. Just proof that the standard playbook isn’t the only one.

10/02/2026

Nel 2023 abbiamo stipulato una convenzione con l’UNIVERSITA' degli Studi di Messina – Dipartimento di Scienze Veterinarie 🏛️🐾 per la RICERCA sui nostri prodotti e sul ruolo dei fitocannabinoidi 🌱 nei processi di infiammazione e neuroinfiammazione negli animali da compagnia🐾.

https://www.frontiersin.org/journals/veterinary-science/articles/10.3389/fvets.2024.1341396/full

Visti gli ottimi risultati ottenuti, la collaborazione è stata rinnovata dopo 10 mesi per avviare un nuovo studio sulla modulazione del dolore nell’osteoartrite cronica 🧪💚

https://www.frontiersin.org/journals/veterinary-science/articles/10.3389/fvets.2024.1496473/full

Questo percorso rappresenta per noi uno dei principali motivi di orgoglio e ci spinge a guardare al futuro con maggiore fiducia 🚀✨

Indirizzo

Viale 1 Maggio 5
Corinaldo

Orario di apertura

Lunedì 08:00 - 18:00
Mercoledì 08:00 - 18:00
Giovedì 08:00 - 18:00
Venerdì 08:00 - 18:00
Sabato 08:00 - 13:00

Telefono

+393287492711

Sito Web

Notifiche

Lasciando la tua email puoi essere il primo a sapere quando ResaPura pubblica notizie e promozioni. Il tuo indirizzo email non verrà utilizzato per nessun altro scopo e potrai annullare l'iscrizione in qualsiasi momento.

Contatta L'azienda

Invia un messaggio a ResaPura:

Scelte rapide

Condividi